AzTrials
AzTrials

Hypotension During SurgeryHPI2022NCT05394896

Hypotension Prediction With HPI Algorithm During Decessed-donor Kidney Transplant (HPI2022)

A study testing ACUMEN (Edwards Lifesciences, Irvine, USA) and Invasive Blood Pressure in people with Hypotension During Surgery and Kidney Transplant; Complications, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

HPI monitoring and the adoption of therapeutic interventions before hypotension occurs should be ensure a shorter time of intra-operative hypotension (MAP < 65 mmHg) during deceased-donor kidney transplant surgery. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
ACUMEN (Edwards Lifesciences, Irvine, USA) and Invasive Blood Pressure
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
46 participants
Where
1 siteItaly
Study dates
1 Nov 2022to 31 Jan 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • First single or double kidney transplant from a cadaveric donor;
  • ASA Class III-IV;
  • Signature of informed consent.

Who cannot join

  • Patient with atrial fibrillation rhythm or high frequency tachyarrhythmias;
  • Severe valvulopathies;
  • Combined single/double kidney-liver-transplant;
  • Patients in whom the need for monitoring would still be expected advanced, invasive or minimally invasive hemodynamic, regardless of the allocation to the study group;

Trial locations and contacts

1 site in 1 country.

Italy1 site, 1 recruiting
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    Bologna, 40100

    Recruiting

Other trials in Italy

About this study

Official title: Hypotension Prediction With HPI Algorithm During Decessed-donor Kidney Transplant: an Explorative, Monocentric, RCT

HPI monitoring and the adoption of therapeutic interventions before hypotension occurs should be ensure a shorter time of intra-operative hypotension (MAP < 65 mmHg) during deceased-donor kidney transplant surgery. The control group is represented by patients undergoing the same surgical procedure with hemodynamic monitoring with invasive blood pressure monitoring which represents the gold standard for this surgery. HPI monitoring has not yet been investigated during this surgery.

Being tested
ACUMEN (Edwards Lifesciences, Irvine, USA), Invasive Blood Pressure
Keywords
HPI

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ACUMEN (Edwards Lifesciences, Irvine, USA)Device

    ACUMEN sensor generates HPI index which should predict hypotension. Based on HPI index, Eadyn and dP/dTmax values anaesthesia should somministrate liquid or drugs to prevent hypotension.

  • Invasive Blood PressureDevice

    Invasive Blood Pressure permits continue monitoring of blood pressure (routine standard for kidney transplant surgery)

Study groups in NCT05394896
Study groupRoleWhat they receive
HPI groupExperimentalConventional therapy and monitoring with ACUMEN sensor (Edwards Lifesciences, Irvine, USA) and Hemosphere platform (Edwards Lifesciences, Irvine, USA) of invasive blood pressure. Strategy to prevent hypotension based on HPI index, Eadyn and dP/dTmax.
Receives: Device: ACUMEN (Edwards Lifesciences, Irvine, USA)
Control groupActive comparatorConventional therapy according to standard monitoring in the operating room which includes invasive blood pressure monitoring.
Receives: Device: Invasive Blood Pressure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intra-operative hypotension time

    Hypotension (MAP < 65 mmHg) time relative to the range from 20 minutes after induction to the end of surgery

    Measured: From 20 minutes after anaesthesia induction to the end of surgery (intra-operative)

Secondary outcomes (9)
  1. Post-operative hypotension time

    Hypotension (MAP < 65 mmHg) time relative to the range from the end of surgery to the first 12 hours after surgery

    Measured: From the end of surgery to the first 12 hours after surgery (post-operative)

  2. Intra-operative severe hypotension time

    Severe hypotension (MAP < 50 mmHg) time relative to the range from 20 minutes after induction to the end of surgery

    Measured: From 20 minutes after anaesthesia induction to the end of surgery (intra-operative)

  3. Major Adverse Cardiovascular Events (MACE)

    Number of major cardiovascular complications (MACE) within the first five days after kidney transplantation (for MACE the composite endpoint of heart attack is considered heart failure, heart failure or presumed cardiac death)

    Measured: First 5 post-operative days after surgery (post-operative)

  4. Hospital mortality

    Number of patient died in the first 30 days after surgery

    Measured: First 30 post-operative days after surgery (post-operative)

  5. Intensive Care Unit Length of Stay

    Number of hours of ICU admission

    Measured: First 30 post-operative days after surgery (post-operative)

  6. Hospital Length of Stay

    Number of days before hospital discharge

    Measured: First 30 post-operative days after surgery (post-operative)

  7. Delayed Graft Function (DGF)

    Need for hemodialysis in first 7 postoperative days

    Measured: First 7 post-operative days (post-operative)

  8. Graft survival

    Measured: 30 days after transplantation

  9. Post-operative delirium

    CAM-ICU positive (asses one time for a day in the first 5 postoperative days)

    Measured: First 5 post-operative days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 May 2022
  2. Study start1 Nov 2022
  3. Primary completion30 Nov 2023 (estimated)
  4. Study completion31 Jan 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
46 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05394896
Sponsor's protocol ID
HPI2022
Acronym
HPI2022
Status last verified
Jan 2023
First submitted
22 May 2022
Last updated
17 Jan 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Biancofiore G, Cecconi M, Rocca GD. A web-based Italian survey of current trends, habits and beliefs in hemodynamic monitoring and management. J Clin Monit Comput. 2015 Oct;29(5):635-42. doi: 10.1007/s10877-014-9646-7. Epub 2014 Dec 12.

    PubMed 25500761
  • Perilli V, Aceto P, Sacco T, Modesti C, Ciocchetti P, Vitale F, Russo A, Fasano G, Dottorelli A, Sollazzi L. Anaesthesiological strategies to improve outcome in liver transplantation recipients. Eur Rev Med Pharmacol Sci. 2016 Jul;20(15):3172-7.

    PubMed 27466988
  • Vincent JL, Rhodes A, Perel A, Martin GS, Della Rocca G, Vallet B, Pinsky MR, Hofer CK, Teboul JL, de Boode WP, Scolletta S, Vieillard-Baron A, De Backer D, Walley KR, Maggiorini M, Singer M. Clinical review: Update on hemodynamic monitoring--a consensus of 16. Crit Care. 2011 Aug 18;15(4):229. doi: 10.1186/cc10291.

    PubMed 21884645
  • Lobo SM, Rezende E, Knibel MF, Silva NB, Paramo JA, Nacul FE, Mendes CL, Assuncao M, Costa RC, Grion CC, Pinto SF, Mello PM, Maia MO, Duarte PA, Gutierrez F, Silva JM Jr, Lopes MR, Cordeiro JA, Mellot C. Early determinants of death due to multiple organ failure after noncardiac surgery in high-risk patients. Anesth Analg. 2011 Apr;112(4):877-83. doi: 10.1213/ANE.0b013e3181e2bf8e. Epub 2010 Jun 8.

    PubMed 20530615
  • Pearse RM, Harrison DA, James P, Watson D, Hinds C, Rhodes A, Grounds RM, Bennett ED. Identification and characterisation of the high-risk surgical population in the United Kingdom. Crit Care. 2006;10(3):R81. doi: 10.1186/cc4928. Epub 2006 Jun 2.

    PubMed 16749940
  • Jhanji S, Thomas B, Ely A, Watson D, Hinds CJ, Pearse RM. Mortality and utilisation of critical care resources amongst high-risk surgical patients in a large NHS trust. Anaesthesia. 2008 Jul;63(7):695-700. doi: 10.1111/j.1365-2044.2008.05560.x. Epub 2008 May 16.

    PubMed 18489613
  • Fischer MO, Fiant AL, Boutros M, Flais F, Filipov T, Debroczi S, Pasqualini L, Rhanem T, Gerard JL, Guittet L, Hanouz JL, Alves A, Parienti JJ; PANEX3 study group. Perioperative hemodynamic optimization using the photoplethysmography in colorectal surgery (the PANEX3 trial): study protocol for a randomized controlled trial. Trials. 2016 Mar 22;17:159. doi: 10.1186/s13063-016-1278-4.

    PubMed 27004412
  • Hamilton MA, Cecconi M, Rhodes A. A systematic review and meta-analysis on the use of preemptive hemodynamic intervention to improve postoperative outcomes in moderate and high-risk surgical patients. Anesth Analg. 2011 Jun;112(6):1392-402. doi: 10.1213/ANE.0b013e3181eeaae5. Epub 2010 Oct 21.

    PubMed 20966436
  • Gomez-Izquierdo JC, Feldman LS, Carli F, Baldini G. Meta-analysis of the effect of goal-directed therapy on bowel function after abdominal surgery. Br J Surg. 2015 May;102(6):577-89. doi: 10.1002/bjs.9747. Epub 2015 Mar 11.

    PubMed 25759947
  • Walsh SR, Tang T, Bass S, Gaunt ME. Doppler-guided intra-operative fluid management during major abdominal surgery: systematic review and meta-analysis. Int J Clin Pract. 2008 Mar;62(3):466-70. doi: 10.1111/j.1742-1241.2007.01516.x. Epub 2007 Nov 21.

    PubMed 18031528

Questions about this trial

What is this clinical trial studying?

A study testing ACUMEN (Edwards Lifesciences, Irvine, USA) and Invasive Blood Pressure in people with Hypotension During Surgery and Kidney Transplant; Complications, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Antonio Siniscalchi, MD (+390512143131, antonio.siniscalchi@aosp.bo.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intra-operative hypotension time (time frame: From 20 minutes after anaesthesia induction to the end of surgery (intra-operative)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05394896, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in